Cipla Ltd fell for a fifth straight session today. The stock is quoting at 589.75, down 0.15% on the day as on 13:24 IST on the NSE. The benchmark NIFTY is up around 0.42% on the day, quoting at 10763.25. The Sensex is at 35375.66, up 0.45%.Cipla Ltd has gained around 5.66% in last one month.Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has increased around 0.23% in last one month and is currently quoting at 8753.25, down 0.16% on the day. The volume in the stock stood at 3.33 lakh shares today, compared to the daily average of 19.09 lakh shares in last one month.

The benchmark May futures contract for the stock is quoting at Rs 593.25, down 0.18% on the day. Cipla Ltd jumped 5.12% in last one year as compared to a 14.41% rally in NIFTY and a 13.52% fall in the Nifty Pharma index.

The PE of the stock is 37.46 based on TTM earnings ending December 17.

Powered by Capital Market - Live News

Cipla announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Phenylephrine Hydrochloride Injection USP, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Pharmacy Bulk Package, Phenylephrine Hydrochloride Injection USP, 10 mg/mL Single- Dose Vial and Exemestane Tablets, 25mg from the United States Food and Drug Administration (USFDA).

Phenylephrine Hydrochloride Injection USP, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Pharmacy Bulk Package, is an AP-rated generic equivalent of Avadel's Vazculep®, and is indicated for the treatment of clinically important hypotension resulting primarily fromvasodilation in the setting of anesthesia. The product will be available for shipping in the near future.

Cipla's Phenylephrine Hydrochloride Injection USP, 10 mg/mL Single-Dose Vial, is an AP-rated generic equivalent of West Ward Pharm Corp's Phenylephrine Hydrochloride Injection, 10 mg/mL, and is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in such settings as septic shock or anesthesia. The product will be available for shipping in the near future.

Cipla's Exemestane Tablets, 25mg, is an AB-rated generic equivalent of Pfizer's Aromasin®, and is indicated for treatment of certain types of breast cancer in postmenopausal women. The product will be available for shipping in the near future.

Vazculep® and generic equivalents had U.S. sales of approximately $56M for the 12-month period ending February 2018, according to IQVIA (IMS) Health. Aromasin® and generic equivalents had U.S. sales of approximately $77M for the 12-month period ending February 2018, according to IMS Health.

The products are manufactured at the company's Goa plant.About Cipla

Powered by Capital Market - Live News

Cipla will hold a meeting of the Board of Directors of the Company on 22 May 2018, to consider and approve audited financial results (standalone and consolidated) for the quarter and year ended 31st March 2018 and recommendation of dividend, if any.

Powered by Capital Market - Live News

Cipla Ltd is down for a fifth straight session today. The stock is quoting at 557.2, down 0.31% on the day as on 13:24 IST on the NSE. The benchmark NIFTY is up around 0.52% on the day, quoting at 10385.15. The Sensex is at 33799, up 0.51%.Cipla Ltd has lost around 4.04% in last one month.Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has increased around 1.66% in last one month and is currently quoting at 8772.4, down 0.33% on the day. The volume in the stock stood at 8.43 lakh shares today, compared to the daily average of 21.99 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 559.9, down 0.36% on the day. Cipla Ltd tumbled 5.5% in last one year as compared to a 13.11% rally in NIFTY and a 15.24% fall in the Nifty Pharma index.

The PE of the stock is 35.45 based on TTM earnings ending December 17.

Powered by Capital Market - Live News